Presentation and Question and Answer Session to be Webcast
beginning at 9:00 a.m. PT on January 11, 2017
WATERTOWN, Mass.--(BUSINESS WIRE)--Dec. 22, 2016--
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
make a formal presentation at the 35th Annual J.P. Morgan
Healthcare Conference on Wednesday, January 11, 2017. The presentation
will contain a business overview and an update on Enanta’s research and
development pipeline. A question and answer session with investors will
follow the presentation.
A live webcast and replay of the presentation, as well as the question
and answer breakout session that follows the presentation will be
accessible by visiting the “Calendar of Events” section on the
“Investors” page of Enanta’s website at www.enanta.com.
The replay webcasts will be available following the presentation and
will be archived for approximately 60 days.
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta’s
research and development efforts are currently focused on four disease
targets: Hepatitis C Virus (HCV), Non-alcoholic Steatohepatitis (NASH),
Respiratory Syncytial Virus (RSV) and Hepatitis B Virus (HBV).
Enanta has discovered novel protease inhibitors that are members of the
direct-acting-antiviral (DAA) inhibitor classes designed for use against
the hepatitis C virus (HCV). These protease inhibitors, developed
through Enanta’s collaboration with AbbVie, include paritaprevir, which
is contained in AbbVie’s marketed DAA regimens for HCV, and glecaprevir
(ABT-493), Enanta’s second protease inhibitor product, which AbbVie has
developed in Phase 3 studies as part of an investigational,
pan-genotypic, once-daily, ribavirin-free, fixed-dose combination (G/P)
with pibrentasvir (ABT-530), AbbVie’s second NS5A inhibitor. AbbVie has
announced it has filed an NDA for G/P with the FDA and is on track to
submit a marketing authorization application for G/P in the European
Union in early 2017.
Enanta has also discovered EDP-305, an FXR agonist product candidate for
NASH, currently in Phase 1 clinical development, as well as a
cyclophilin inhibitor, EDP-494, a novel host-targeting mechanism for
HCV, which is also in Phase 1 clinical development. In addition, Enanta
has early lead candidates for HBV and RSV in preclinical development.
Please visit www.enanta.com
for more information on Enanta’s programs and pipeline.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161222005683/en/
Source: Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710